Julianne Bruno sold $59k of CRSP
Chief Operating Officer at CRISPR Therapeutics AG. 1,388 shares at an average of $42.54, traded Mar 11, 2025, filed Mar 12, 2025.
Score components
- +20RoleCOO
- +7Trade size$59k at market
- +5Share of holdings soldSold 15% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-038214, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | MOption exercise Common Shares | +2,399 | - | - | 9,461 | Mar 12, 2025 |
| Mar 11, 2025 | SOpen-market sale Common Shares | -1,198 | $42.42 | $51k | 8,263 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Common Shares | +435 | - | - | 8,698 | Mar 12, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Shares | -190 | $43.32 | $8,231 | 8,508 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,399 | - | - | 4,796 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Restricted Stock Unitsderivative | -435 | - | - | 0 | Mar 12, 2025 |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 40Moderate | CRISPR Therapeutics AG | Ali Behbahani director | $781k 13,679 shares | -45% | |
| 21Weak | CRSPsell CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $141k 3,932 shares | -39% | |
| 33Weak | CRISPR Therapeutics AG | Julianne Bruno Chief Operating Officer | $71k 1,714 shares | -14% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $131k 3,185 shares | -4% | |
| 36Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $91k 2,197 shares | -12% | |
| 41Moderate | CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $414k 10,031 shares | -5% | |
| 38Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $157k 3,762 shares | -23% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $169k 3,966 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.